Glioma Clinical Trial - FCI in Post-operative Low Grade Gliomas

Status Recruiting

Clinical Trial Summary

The aim of this pilot study is to explore the utility of a new imaging technique, called Field Cycling Imaging (FCI), in postoperative low grade gliomas. The main question it aims to answer is if FCI can differentiate subtypes of low grade gliomas. Participants will have one FCI scan.

Clinical Trial Description

Standard clinical magnetic resonance imaging (MRI) is the mainstay of diagnosis in brain lesions. It is a powerful imaging technique for the non-invasive investigation of the brain and has been an incredibly successful technology since its commercialisation in the 1980s largely due to its excellent spatial resolution and ability to distinguish multiple tissues in multiple planes. When exogenous contrast agents are used, MRI can demonstrate the breakdown of the blood-brain barrier and provide additional physiological information. However, standard MRI has limitations in determining the subtypes of tumours, which originate from different cells and therefore contain differing types of proteins. The aim of this project is to establish if there is a difference in the relaxometry (i.e., loss of MRI signal over time) characteristics of different brain lesions using Field Cycling Imaging (FCI), which is a new technology being developed at the University of Aberdeen. FCI combines the use of a moderately high magnetic field with the ability to probe low magnetic fields so that one can preserve image resolution while also exploiting the high contrast present at low magnetic fields. This provides quantitative data on the molecular dynamics in the tissues, completely non-invasively. For this study, the research team will use FCI to try to establish if there is a difference in the relaxometry characteristics of different low-grade gliomas. Ten patients with postoperative low grade glioma will be included. Each participant will be asked to undergo one FCI scan only. FCI images will be acquired on dedicated equipment, specifically built for the purpose of imaging human volunteers and patients. Participants will carry on receiving their routine clinical care before and after their scan. ;

Study Design

Related Conditions & MeSH terms

Glioma

Clinical Trial Details

NCT number	NCT06294418
Study type	Interventional
Source	NHS Grampian
Contact	Celia G Alvarez Campano, Dr
Phone	+441224437828
Email	celia.alvarezcampano@abdn.ac.uk
Status	Recruiting
Phase	N/A
Start date	February 15, 2024
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04539574` - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors	N/A
Enrolling by invitation	`NCT04461002` - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Completed	`NCT03242824` - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma	Phase 2
Recruiting	`NCT04186832` - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy	N/A
Completed	`NCT00424554` - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)	Phase 2
Recruiting	`NCT05968053` - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting	`NCT04550663` - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Phase 1
Completed	`NCT02805179` - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma	Phase 2
Terminated	`NCT04556929` - Enhanced Detection in Glioma Excision	N/A
Not yet recruiting	`NCT06408428` - Glioma Intraoperative MicroElectroCorticoGraphy	N/A
Recruiting	`NCT06043232` - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting	`NCT06043765` - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training	N/A
Not yet recruiting	`NCT05025969` - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed	`NCT02978261` - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	Phase 1
Terminated	`NCT01502605` - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas	Phase 1
Completed	`NCT01836536` - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients	N/A
Completed	`NCT01479686` - iMRI Guided Resection in Cerebral Glioma Surgery	Phase 3
Completed	`NCT01212731` - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Withdrawn	`NCT00985036` - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.